These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 11038485)

  • 1. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
    Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W
    Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor (VEGF)--a valuable serum tumour marker in patients with colorectal cancer?
    Broll R; Erdmann H; Duchrow M; Oevermann E; Schwandner O; Markert U; Bruch HP; Windhövel U
    Eur J Surg Oncol; 2001 Feb; 27(1):37-42. PubMed ID: 11237490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.
    Heer K; Kumar H; Read JR; Fox JN; Monson JR; Kerin MJ
    Clin Cancer Res; 2001 Nov; 7(11):3491-4. PubMed ID: 11705867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
    Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
    Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
    Wu Y; Saldana L; Chillar R; Vadgama JV
    Int J Oncol; 2002 Mar; 20(3):509-16. PubMed ID: 11836562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
    Coskun U; Günel N; Toruner FB; Sancak B; Onuk E; Bayram O; Cengiz O; Yilmaz E; Elbeg S; Ozkan S
    Neoplasma; 2003; 50(1):41-6. PubMed ID: 12687277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating vascular endothelial growth factor in patients with colorectal cancer.
    Fujisaki K; Mitsuyama K; Toyonaga A; Matsuo K; Tanikawa K
    Am J Gastroenterol; 1998 Feb; 93(2):249-52. PubMed ID: 9468253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S; Szmitkowski M; Wojtukiewicz M
    Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
    Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
    Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer.
    Lantzsch T; Hefler L; Krause U; Kehl A; Goepel C; Koelbl H; Dunst J; Lampe D
    Anticancer Res; 2002; 22(3):1925-8. PubMed ID: 12168895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum vascular endothelial growth factor is often elevated in disseminated cancer.
    Salven P; Mänpää H; Orpana A; Alitalo K; Joensuu H
    Clin Cancer Res; 1997 May; 3(5):647-51. PubMed ID: 9815732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC; Day W; Jones B; Loo WT; Chow LW
    Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical importance of determination of tumor markers during follow-up in breast carcinoma].
    Fínek J; Holubec L; Topolcan O; Pikner R; Sůvová B; Treska V
    Cas Lek Cesk; 2004; 143(3):174-7. PubMed ID: 15134036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
    Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
    Shang ZJ; Li JR; Li ZB
    Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
    Pan QR; Zhang X; Xu ZF; Zheng S
    Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.